Danaher stock kpis
Want to see DHR full AI Analyst Report?
Recurring Revenue
Danaher reported recurring revenue of $5.40B in Q3 2026, up 3.8% from Q2 2026 and up 7.6% year over year. The highest value was $5.98B in Q4 2021.
Measures the portion of revenue expected to continue in the future, indicating business stability and potential for sustained growth.
Recurring revenue has moved from a mid‑$4B base into a steadier ~$5B run rate with clear multi‑year growth and stronger momentum through 2025–H1‑2026; however, quarter‑to‑quarter spikes and the pronounced year‑end troughs reflect timing/seasonality (respiratory testing swings) and bioprocessing shipment timing rather than a loss of underlying demand. Management’s M&A (Masimo closed, StatLab pending) and strong FCF support durable recurring mix expansion and buybacks, but expect lumpy quarterly cadence even as core recurring growth remains intact.
DHR Recurring Revenue
| Period | Recurring Revenue |
|---|---|
| Q3 2026Sep 30, 2026 | $5.40B |
| Q2 2026Jun 30, 2026 | $5.20B |
| Q1 2026Mar 31, 2026 | $5.03B |
| Q4 2025Dec 31, 2025 | $5.32B |
| Q3 2025Sep 30, 2025 | $5.02B |
| Q2 2025Jun 30, 2025 | $4.97B |
| Q1 2025Mar 31, 2025 | $4.82B |
| Q4 2024Dec 31, 2024 | $5.11B |
| Q3 2024Sep 30, 2024 | $4.78B |
| Q2 2024Jun 30, 2024 | $4.69B |
| Q1 2024Mar 31, 2024 | $4.79B |
| Q4 2023Dec 31, 2023 | $2.78B |
| Q3 2023Sep 30, 2023 | $5.18B |
| Q2 2023Jun 30, 2023 | $5.34B |
| Q1 2023Mar 31, 2023 | $5.39B |
| Q4 2022Dec 31, 2022 | $3.26B |
| Q3 2022Sep 30, 2022 | $5.83B |
| Q2 2022Jun 30, 2022 | $5.89B |
| Q1 2022Mar 31, 2022 | $5.90B |
| Q4 2021Dec 31, 2021 | $5.98B |
| Q3 2021Sep 30, 2021 | $5.42B |
| Q2 2021Jun 30, 2021 | $5.32B |
| Q1 2021Mar 31, 2021 | $5.08B |
| Q4 2020Dec 31, 2020 | $4.73B |
| Q3 2020Sep 30, 2020 | $4.23B |
| Q2 2020Jun 30, 2020 | $3.81B |
| Q1 2020Mar 31, 2020 | $3.21B |
| Q4 2019Dec 31, 2019 | $1.74B |
| Q3 2019Sep 30, 2019 | $3.50B |
| Q2 2019Jun 30, 2019 | $3.61B |
| Q1 2019Mar 31, 2019 | $3.46B |
| Q4 2018Dec 31, 2018 | $1.52B |
| Q3 2018Sep 30, 2018 | $3.35B |
| Q2 2018Jun 30, 2018 | $3.49B |
| Q1 2018Mar 31, 2018 | $3.32B |

